Evidence map›Paper›PMID 34944463›Full record

ReviewBiomolecules2021

The Use of Fluorescent Anti-CEA Antibodies to Label, Resect and Treat Cancers: A Review.

Michael A Turner, Thinzar M Lwin, Siamak Amirfakhri, Hiroto Nishino, Robert M Hoffman, Paul J Yazaki, Michael Bouvet

Open access · goldAbstract readReview
In one paragraph

Review in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Michael A TurnerVA San Diego Healthcare System, La Jolla, CA 92161, USA.ORCID 0000-0001-8949-3136
Thinzar M LwinDana-Farber Cancer Institute, Boston, MA 02215, USA.
Siamak AmirfakhriVA San Diego Healthcare System, La Jolla, CA 92161, USA.
Hiroto NishinoVA San Diego Healthcare System, La Jolla, CA 92161, USA.
Robert M HoffmanVA San Diego Healthcare System, La Jolla, CA 92161, USA.
Paul J YazakiDepartment of Immunology and Theranostics, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.
Michael BouvetVA San Diego Healthcare System, La Jolla, CA 92161, USA.ORCID 0000-0002-0086-2159
University of California San Diego · USCity Of Hope National Medical Center · USDana-Farber Cancer Institute · US

Funding

UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
NCI NIH HHS T32 CA121938NIH HHS T32CA121938
6 · The paper itself

Abstract

A major barrier to the diagnosis and effective treatment of solid-tumor cancers is the difficulty in detection and visualization of tumor margins in primary and metastatic disease. The use of fluorescence can augment the surgeon's ability to detect cancer and aid in its resection. Several cancer types express carcinoembryonic antigen (CEA) including colorectal, pancreatic and gastric cancer. Antibodies to CEA have been developed and tagged with near-infrared fluorescent dyes. This review article surveyed the use of CEA antibodies conjugated to fluorescent probes for in vivo studies since 1990. PubMed and Google Scholar databases were queried, and 900 titles and abstracts were screened. Fifty-nine entries were identified as possibly meeting inclusion/exclusion criteria and were reviewed in full. Forty articles were included in the review and their citations were screened for additional entries. A total of 44 articles were included in the final review. The use of fluorescent anti-CEA antibodies has been shown to improve detection and resection of tumors in both murine models and clinically. The cumulative results indicate that fluorescent-conjugated anti-CEA antibodies have important potential to improve cancer diagnosis and surgery. In an emerging technology, anti-CEA fluorescent antibodies have also been successfully used for photoimmunotherapy treatment for cancer.

Indexed as

Carcinoembryonic AntigenFluorescent DyesNeoplasmsAnimalsAntibodiesHumansAntibodiesCarcinoembryonic AntigenFluorescent Dyescarcinoembryonic antigenCEAFGSfluorescencefluorescence-guided surgeryfluorescence labelinginfrared dyes

Identifiers

PMID34944463
PMCPMC8699160
OpenAlexW3216064163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.